ESPR Esperion Therapeutics, Inc. revenue, earnings and financials

For the quarter ended March 31, 2026, Esperion Therapeutics, Inc. reported revenue of $80.1M (up 23.2% from a year earlier), net income of −$25.2M and diluted EPS of −$0.10; over the last four quarters revenue was $418M and net income −$7.42M; for the fiscal year ended December 2025 revenue was $403M, up 21.3% on the year before.

ESPR annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $403M, gross profit n/a, operating income $60.3M, net income −$22.7M (margin -5.6%), EPS −$0.11
• Fiscal year ended Dec 2024: revenue $332M, gross profit n/a, operating income $54.4M, net income −$51.7M (margin -15.6%), EPS −$0.28
• Fiscal year ended Dec 2023: revenue $116M, gross profit n/a, operating income −$156M, net income −$209M (margin -179.9%), EPS −$2.03
• Fiscal year ended Dec 2022: revenue $75.5M, gross profit n/a, operating income −$180M, net income −$234M (margin -309.6%), EPS −$3.52
• Fiscal year ended Dec 2021: revenue $78.4M, gross profit n/a, operating income −$227M, net income −$269M (margin -343.0%), EPS −$9.31

ESPR quarterly revenue and earnings

• Quarter ended Mar 31, 2026: revenue $80.1M (up 23.2% year over year), net income −$25.2M, EPS −$0.10
• Quarter ended Dec 31, 2025 (from the annual report): revenue $168M (up 143.7% year over year), net income $61.8M, EPS $0.32
• Quarter ended Sep 30, 2025: revenue $87.3M (up 69.1% year over year), net income −$31.3M, EPS −$0.16
• Quarter ended Jun 30, 2025: revenue $82.4M (up 11.6% year over year), net income −$12.7M, EPS −$0.06
• Quarter ended Mar 31, 2025: revenue $65.0M (down 52.8% year over year), net income −$40.5M, EPS −$0.21
• Quarter ended Dec 31, 2024 (from the annual report): revenue $69.1M (up 114.3% year over year), net income −$21.3M, EPS −$0.14
• Quarter ended Sep 30, 2024: revenue $51.6M (up 52.0% year over year), net income −$29.5M, EPS −$0.15
• Quarter ended Jun 30, 2024: revenue $73.8M (up 186.3% year over year), net income −$61.9M, EPS −$0.33
• Quarter ended Mar 31, 2024: revenue $138M (up 466.1% year over year), net income $61.0M, EPS $0.34
• Quarter ended Dec 31, 2023 (from the annual report): revenue $32.3M (up 71.4% year over year), net income −$56.3M, EPS −$0.41
• Quarter ended Sep 30, 2023: revenue $34.0M (up 79.0% year over year), net income −$41.3M, EPS −$0.37
• Quarter ended Jun 30, 2023: revenue $25.8M (up 36.9% year over year), net income −$49.9M, EPS −$0.46
• Quarter ended Mar 31, 2023: revenue $24.3M (up 29.2% year over year), net income −$61.7M, EPS −$0.79
• Quarter ended Dec 31, 2022 (from the annual report): revenue $18.8M (up 22.2% year over year), net income −$55.5M, EPS −$0.73
• Quarter ended Sep 30, 2022: revenue $19.0M (up 31.7% year over year), net income −$55.1M, EPS −$0.81
• Quarter ended Jun 30, 2022: revenue $18.8M (down 53.7% year over year), net income −$66.3M, EPS −$1.05
• Quarter ended Mar 31, 2022: revenue $18.8M (up 136.1% year over year), net income −$56.7M, EPS −$0.93
• Quarter ended Dec 31, 2021 (from the annual report): revenue $15.4M, net income −$65.1M, EPS −$1.52
• Quarter ended Sep 30, 2021: revenue $14.4M, net income −$69.4M, EPS −$2.62
• Quarter ended Jun 30, 2021: revenue $40.7M, net income −$43.7M, EPS −$1.67

ESPR cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$13.1M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$23.7M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$135M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$175M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$264M, share buybacks $0

ESPR balance sheet

• Mar 31, 2026: cash $156M, total assets $463M, total liabilities $770M, shareholders' equity −$308M
• Dec 31, 2025: cash $168M, total assets $466M, total liabilities $768M, shareholders' equity −$302M
• Sep 30, 2025: cash $92.4M, total assets $364M, total liabilities $815M, shareholders' equity −$451M
• Jun 30, 2025: cash $86.1M, total assets $347M, total liabilities $781M, shareholders' equity −$434M
• Mar 31, 2025: cash $115M, total assets $324M, total liabilities $750M, shareholders' equity −$426M
• Dec 31, 2024: cash $145M, total assets $344M, total liabilities $733M, shareholders' equity −$389M
• Sep 30, 2024: cash $145M, total assets $314M, total liabilities $684M, shareholders' equity −$370M
• Jun 30, 2024: cash $189M, total assets $352M, total liabilities $697M, shareholders' equity −$344M

What is ESPR's revenue?

Esperion Therapeutics, Inc. reported $418M of revenue over its last four quarters, through March 31, 2026.

Is ESPR profitable?

No. Esperion Therapeutics, Inc. lost $7.42M over the last four quarters.

What is ESPR's EPS?

Diluted earnings per share over the last four quarters were $0.00; −$0.10 in the latest quarter.

ESPR ownership and insider trades · All stocks